$OVID
Ovid Therapeutics Inc.

2019 Q4 Form 10-K Financial Statement

#000156459020010108 Filed on March 11, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.200M $5.200M $19.30M
YoY Change 15.56% 13.04% 1.05%
% of Gross Profit
Research & Development $12.10M $11.60M $42.16M
YoY Change 40.7% 35.73% 24.76%
% of Gross Profit
Depreciation & Amortization $100.0K $10.00K $255.0K
YoY Change 42.86% 79.92%
% of Gross Profit
Operating Expenses $17.27M $16.77M $42.16M
YoY Change 31.65% 27.24% -20.35%
Operating Profit -$16.77M -$61.41M
YoY Change 16.02%
Interest Expense $300.0K $100.0K $900.0K
YoY Change 50.0% -50.0% -10.0%
% of Operating Profit
Other Income/Expense, Net $299.0K $131.0K
YoY Change 38.43% -38.79%
Pretax Income -$17.00M -$16.60M -$60.50M
YoY Change 31.78% 27.69% 16.35%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$16.97M -$16.63M -$60.50M
YoY Change 31.53% 28.33% 16.39%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$344.8K -$431.2K -$1.543M
COMMON SHARES
Basic Shares Outstanding 38.69M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.74M $37.90M $76.70M
YoY Change 84.91% -27.81% 84.82%
Cash & Equivalents $41.90M $37.91M $41.40M
Short-Term Investments $34.84M $0.00 $34.80M
Other Short-Term Assets $1.900M $1.200M $1.900M
YoY Change -32.14% -55.56% -32.14%
Inventory
Prepaid Expenses
Receivables $1.100M $0.00 $1.100M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $79.81M $39.15M $79.80M
YoY Change 80.29% -29.14% 80.14%
LONG-TERM ASSETS
Property, Plant & Equipment $68.36K $72.24K $100.0K
YoY Change -2.15% -27.76% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $467.2K $351.3K $1.000M
YoY Change 19.23% -93.11% -69.7%
Total Long-Term Assets $1.031M $1.544M $1.000M
YoY Change -69.52% -70.0% -69.7%
TOTAL ASSETS
Total Short-Term Assets $79.81M $39.15M $79.80M
Total Long-Term Assets $1.031M $1.544M $1.000M
Total Assets $80.84M $40.69M $80.80M
YoY Change 69.66% -32.63% 69.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.256M $5.342M $3.300M
YoY Change -13.3% 16.12% -13.16%
Accrued Expenses $7.267M $4.682M $7.300M
YoY Change 42.8% -19.28% 43.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.53M $10.36M $10.50M
YoY Change 19.1% -0.37% 19.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K $300.0K $300.0K
YoY Change
Total Long-Term Liabilities $300.0K $300.0K $300.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.53M $10.36M $10.50M
Total Long-Term Liabilities $300.0K $300.0K $300.0K
Total Liabilities $10.82M $10.65M $10.80M
YoY Change 22.34% 2.38% 22.73%
SHAREHOLDERS EQUITY
Retained Earnings -$213.2M -$196.2M
YoY Change 39.6%
Common Stock $283.2M $226.2M
YoY Change 47.87% 19.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $70.02M $30.05M $70.00M
YoY Change
Total Liabilities & Shareholders Equity $80.84M $40.69M $80.80M
YoY Change 69.66% -32.63% 69.75%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019
OPERATING ACTIVITIES
Net Income -$16.97M -$16.63M -$60.50M
YoY Change 31.53% 28.33% 16.39%
Depreciation, Depletion And Amortization $100.0K $10.00K $255.0K
YoY Change 42.86% 79.92%
Cash From Operating Activities -$16.90M -$9.500M -$51.09M
YoY Change 53.64% -5.94% 12.14%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K $0.00 $57.16K
YoY Change 100.0% -100.0% 68.75%
Acquisitions
YoY Change
Other Investing Activities -$34.80M $0.00 -$29.80M
YoY Change -304.71% -100.0% 496.0%
Cash From Investing Activities -$35.00M $0.00 -$30.04M
YoY Change -307.1% -100.0% 460.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $64.12M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 55.80M 100.0K 86.54M
YoY Change 0.0% 30143.66%
NET CHANGE
Cash From Operating Activities -16.90M -9.500M -51.09M
Cash From Investing Activities -35.00M 0.000 -30.04M
Cash From Financing Activities 55.80M 100.0K 86.54M
Net Change In Cash 3.900M -9.400M 5.408M
YoY Change -33.9% -218.99% -110.68%
FREE CASH FLOW
Cash From Operating Activities -$16.90M -$9.500M -$51.09M
Capital Expenditures -$200.0K $0.00 $57.16K
Free Cash Flow -$16.70M -$9.500M -$51.15M
YoY Change 53.21% -5.0% 12.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Registrant Name
EntityRegistrantName
Ovid Therapeutics Inc.
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001636651
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q2 dei Entity Public Float
EntityPublicFloat
25500000
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2019 dei Trading Symbol
TradingSymbol
OVID
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity File Number
EntityFileNumber
001-38085
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5270895
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
1460 Broadway
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 15044
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
CY2019 dei City Area Code
CityAreaCode
646
CY2019 dei Local Phone Number
LocalPhoneNumber
661-7661
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41897144
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36489618
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
34841969
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
5011034
CY2019Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
1131146
CY2018Q4 us-gaap Accounts Receivable Related Parties
AccountsReceivableRelatedParties
600104
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1942933
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2167391
CY2019Q4 us-gaap Assets Current
AssetsCurrent
79813192
CY2018Q4 us-gaap Assets Current
AssetsCurrent
44268147
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10533608
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8844457
CY2019Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
286562
CY2018Q4 us-gaap Liabilities
Liabilities
8844457
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1829
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19141652
CY2018 us-gaap Operating Expenses
OperatingExpenses
52931683
CY2019Q4 us-gaap Liabilities
Liabilities
10820170
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
8
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
24654
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
54711
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
283122894
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191477598
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2469
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213156521
CY2019Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
359539
CY2018Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
2797561
CY2019Q4 us-gaap Security Deposit
SecurityDeposit
135390
CY2018Q4 us-gaap Security Deposit
SecurityDeposit
122155
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
68363
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69867
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
467247
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
391872
CY2019Q4 us-gaap Assets
Assets
80843731
CY2018Q4 us-gaap Assets
Assets
47649602
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3256098
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3755595
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7266706
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5088862
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
10804
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152695278
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
38805145
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47649602
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-52931683
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
952073
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24654114
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24654114
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33790031
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-51979610
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-51979610
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1829
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51981439
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
131895
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5205792
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4298
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
83436503
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
111378
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
174762
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7063941
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1829
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
5205792
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
7063941
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
255002
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
141733
CY2018 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-4610
CY2019 ovid Accrued Interest And Accretion Of Discounts Short Term Investments
AccruedInterestAndAccretionOfDiscountsShortTermInvestments
-29633
CY2018 ovid Accrued Interest And Accretion Of Discounts Short Term Investments
AccruedInterestAndAccretionOfDiscountsShortTermInvestments
-1240
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-224458
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1305047
CY2019 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-13235
CY2018 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-33215
CY2019 us-gaap Increase Decrease Due From Affiliates
IncreaseDecreaseDueFromAffiliates
531042
CY2019 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
-2438022
CY2018 ovid Increase Decrease In Prepaid Expense Noncurrent
IncreaseDecreaseInPrepaidExpenseNoncurrent
2192915
CY2019 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-653953
CY2018 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1649735
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2177844
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1093528
CY2019 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
297366
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51090622
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45558480
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
34797004
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
50011623
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
5000000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
45000000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57156
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33871
CY2019 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
186889
CY2018 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
318148
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30041049
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5363642
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64120736
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
131895
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
174762
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
111378
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86539197
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
286140
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5407526
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-50635982
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36489618
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87125600
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41897144
CY2019 us-gaap Noninterest Expense Offering Cost
NoninterestExpenseOfferingCost
69628
CY2019 ovid Software Development And Other Costs In Accounts Payable And Accrued Expenses
SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses
164922
CY2018 ovid Software Development And Other Costs In Accounts Payable And Accrued Expenses
SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses
60624
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
19470
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(B) <font style="color:#000000;">Use of Estimates</font></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</font></p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(C) Risks and Uncertainties</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its drug candidates, ability to obtain regulatory approval of its drug candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition and untested manufacturing capabilities</font>.</p>
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.07
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.65
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
76700000
CY2019 ovid Description Of Ownership Pattern As Per License And Collaboration Agreement
DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement
Ovid and Takeda are sharing 50/50 in the drug development and throughout the life of this compound
CY2019 ovid Percentage Of Net Expenses Of Development Costs Recorded In Research And Development
PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment
0.50
CY2019 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method.
CY2019 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019 us-gaap Defined Contribution Plan Plan Name
DefinedContributionPlanPlanName
401(k)-retirement plan
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
285000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
210034
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
41897144
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
41897144
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
34839500
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2469
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
36489618
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
36489618
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
5012863
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1829
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
5000000
CY2019Q4 ovid Debt Securities Available For Sale Continuous Unrealized Gain Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPositionLessThan12Months
34800000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2019Q4 ovid Debt Securities Available For Sale Continuous Unrealized Gain Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions
0
CY2019 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
125354
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
86164
CY2019 us-gaap Depreciation
Depreciation
39000
CY2018 us-gaap Depreciation
Depreciation
35000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
467000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
392000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
216000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
106000
CY2019Q4 ovid Clinical Trials Accrual Current
ClinicalTrialsAccrualCurrent
3235527
CY2018Q4 ovid Clinical Trials Accrual Current
ClinicalTrialsAccrualCurrent
1352133
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2728495
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2779021
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1070589
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
772785
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
232095
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
184923
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2337931
CY2019 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share held
CY2019Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
30500000
CY2019Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
33500000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3547513
CY2019Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
33500000
CY2019 us-gaap Dividend Payment Restrictions Schedule Description
DividendPaymentRestrictionsScheduleDescription
No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid.
CY2019 us-gaap Dividends
Dividends
0
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5205792
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7063941
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4298802
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1733673
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1440578
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15744
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1009253
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4714383
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
856601
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7405295
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3296547
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.23
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.07
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.16
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.10
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.88
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.93
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.43
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.82
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.93
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M25D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y11M1D
CY2018 ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y3M3D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M20D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2019 ovid Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P9Y6M21D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y6M10D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8174686
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3865036
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
153485
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
153485
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4488930
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
356443
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9837812
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M2D
CY2019 ovid Operating Loss Carryforwards Expiration Period Start
OperatingLossCarryforwardsExpirationPeriodStart
2035
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
22467000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18748000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
76463170
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
54032804
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
57288334
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37195164
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3351315
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1737870
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6606889
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5333006
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
898067
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
869446
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
22026
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
19949
CY2019Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
132072
CY2018Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
88353
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
8208519
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
8828914
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
76463170
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54032804
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
253000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
265000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13801000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13057000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16635000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
131000
CY2019Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
299000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-13801000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-13057000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-16635000
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16968000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-16968000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.1380
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.1362
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0050
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0061
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3714
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3602
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0267
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0197
CY2019 us-gaap Related Party Transaction Terms And Manner Of Settlement
RelatedPartyTransactionTermsAndMannerOfSettlement
any time and for any reason, upon thirty (30) days written notice to the other party.
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
14054000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
13322000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
16766000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
17267000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
13430000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
13210000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
13176000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
13116000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
247000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
275000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
214000
CY2018Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
216000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-13183000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-12935000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-12962000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-12900000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13183000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12935000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12962000
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12900000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52

Files In Submission

Name View Source Status
0001564590-20-010108-index-headers.html Edgar Link pending
0001564590-20-010108-index.html Edgar Link pending
0001564590-20-010108.txt Edgar Link pending
0001564590-20-010108-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gb2h2v1c1o5p000001.jpg Edgar Link pending
gb2h2v1c1o5p000002.jpg Edgar Link pending
gb2h2v1c1o5p000003.jpg Edgar Link pending
gb2h2v1c1o5p000004.jpg Edgar Link pending
gb2h2v1c1o5p000005.jpg Edgar Link pending
gb2h2v1c1o5p000006.jpg Edgar Link pending
gb2h2v1c1o5p000007.jpg Edgar Link pending
gb2h2v1c1o5p000008.jpg Edgar Link pending
gb2h2v1c1o5p000009.jpg Edgar Link pending
gb2h2v1c1o5p000010.jpg Edgar Link pending
gb2h2v1c1o5p000011.jpg Edgar Link pending
gb2h2v1c1o5p000012.jpg Edgar Link pending
gb2h2v1c1o5p000013.jpg Edgar Link pending
gb2h2v1c1o5p000014.jpg Edgar Link pending
gb2h2v1c1o5p000015.jpg Edgar Link pending
gb2h2v1c1o5p000016.jpg Edgar Link pending
gb2h2v1c1o5p000017.jpg Edgar Link pending
gb2h2v1c1o5p000018.jpg Edgar Link pending
gb2h2v1c1o5p000019.jpg Edgar Link pending
gb2h2v1c1o5p000020.jpg Edgar Link pending
gb2h2v1c1o5p000021.jpg Edgar Link pending
gb2h2v1c1o5p000022.jpg Edgar Link pending
gb2h2v1c1o5p000023.jpg Edgar Link pending
ovid-10k_20191231.htm Edgar Link pending
ovid-20191231.xml Edgar Link completed
ovid-20191231.xsd Edgar Link pending
ovid-20191231_cal.xml Edgar Link unprocessable
ovid-20191231_def.xml Edgar Link unprocessable
ovid-20191231_lab.xml Edgar Link unprocessable
ovid-20191231_pre.xml Edgar Link unprocessable
ovid-ex1013_750.htm Edgar Link pending
ovid-ex1015_795.htm Edgar Link pending
ovid-ex1016_797.htm Edgar Link pending
ovid-ex231_6.htm Edgar Link pending
ovid-ex311_9.htm Edgar Link pending
ovid-ex312_8.htm Edgar Link pending
ovid-ex321_7.htm Edgar Link pending
ovid-ex43_544.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending